Sensitive, specific and accurate determination of an analyte or biomarker is critical for diagnosis, therapy, drug & vaccine safety. However, the complex nature of sample matrices poses a challenge to obtaining a reliable result, especially for those analytes and biomarkers with low abundance but high significance. For example, IgE-mediated anaphylaxis is life-threatening. Detection of pre-existing allergen-specific IgE can identify individuals at risk. By removing the internal background of each analyte, our proprietary FocalTuning™ platform and products (US10,914,731B2, 2021; US11,835,517B2, 2023; ZL202080015982.5, 2024) can detect and quantify low level analytes such as polyethylene glycol (PEG) specific IgE, which has received increasing attention in severe hypersensitivity reactions of PEG and PEG-containing products, including food, cosmetics, daily life products, mRNA vaccines and PEGylated drugs. This general platform can also be applied to the early diagnosis of various diseases including cancer.
![](https://i0.wp.com/leadinglifetechnologies.com/wp-content/uploads/2022/05/Focaltuning-1-copy-1024x379.jpg?resize=525%2C194&ssl=1)
The technological advantages of FocalTuning™ platform include, but are not limited to
- Removing sample background of each analyte
- Patented technology
- Unbeatable accuracy
- Small sample size
- Powerful statistics
FocalTuning Platform Flow Chart (use anti-PEG detection as example)
![](https://i0.wp.com/leadinglifetechnologies.com/wp-content/uploads/2022/09/Flow-chart-1-copy.jpg?resize=525%2C702)
![](https://i0.wp.com/leadinglifetechnologies.com/wp-content/uploads/2022/09/Flow-chart-2-copy.jpg?resize=525%2C697)
![](https://i0.wp.com/leadinglifetechnologies.com/wp-content/uploads/2022/09/Flow-chart-3-copy.jpg?resize=525%2C699)